Gonadorelin (GnRH (Gonadotropin-Releasing Hormone))

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a decapeptide produced by the hypothalamus that controls the entire downstream reproductive hormone cascade. Its amino acid sequence is pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, identical to endogenous human GnRH. The story of gonadorelin in TRT protocols really starts in 2020, when the FDA reclassified HCG from a drug to a biologic. This reclassification threw the TRT world into chaos. Compounding pharmacies that had been producing HCG for years suddenly faced new regulatory hurdles, and many stopped carrying it. TRT clinics needed an alternative to maintain patients' testicular function, and gonadorelin was the logical choice. The pharmacology makes sense on paper. In the natural hormonal cascade, the hypothalamus releases GnRH in pulses every 60-90 minutes. Each pulse hits the pituitary and triggers LH and FSH release. LH then travels to the testes and stimulates testosterone production. When a man takes exogenous testosterone, this cascade shuts down at the top: the hypothalamus stops pulsing GnRH. Gonadorelin skips the hypothalamus entirely and delivers the GnRH signal directly. There's an important nuance here. GnRH's effect depends entirely on how it's administered. Pulsatile dosing (mimicking natural pulses) stimulates gonadotropin release. Continuous dosing does the opposite, desensitizing the GnRH receptor and shutting down LH/FSH. This is the same principle behind GnRH agonists like leuprolide, which are given continuously to suppress testosterone in prostate cancer treatment. For TRT purposes, the standard protocol is 100-200 mcg injected subcutaneously twice daily, spaced about 12 hours apart. This twice-daily dosing doesn't perfectly replicate the body's ultradian GnRH pulses (which occur every 60-90 minutes), but it appears sufficient to maintain gonadotropin secretion in most patients. Some clinics use once-daily dosing with reported success. The honest assessment of gonadorelin vs. HCG comes down to this: HCG has stronger clinical evidence for maintaining intratesticular testosterone during TRT (the Coviello 2005 study measured this directly). Gonadorelin's evidence base for this specific application is thinner, relying more on pharmacological reasoning and growing clinical experience than on randomized controlled trials. But it works through a more physiological pathway, it's not affected by the biologic reclassification, and many clinicians report satisfactory outcomes. Gonadorelin's extremely short half-life (10-40 minutes) is both its advantage and its limitation. The advantage is that there's minimal accumulation and low risk of sustained receptor desensitization with proper spacing. The limitation is that the stimulatory signal is brief, raising questions about whether twice-daily dosing provides enough cumulative stimulation compared to HCG's 24-36 hour signal. Storage is straightforward: lyophilized gonadorelin is stable at room temperature. Once reconstituted with bacteriostatic water, store at 2-8C and use within 14-28 days depending on the pharmacy's beyond-use dating.